一、計畫目標
 

為超前部署重點特色領域措施—布局產業前瞻先期技術,依第十一次全國科學技術會議,科技部推動「產業創新人才海外培訓計畫」(X Talent,以下簡稱「本計畫」),以延續原博士創新之星計畫(LEAP)培育創新創業人才之精神,並配合政府推動之「六大核心戰略產業」,選送台灣產學創新種子人才赴海外研習,以因應美中貿易戰及後疫情時代的產業轉型及新興產業發展需求,希冀種子人才返國後協助產業創新布局及發展,讓台灣在全球科技戰略布局,精準掌握市場先機,在未來成為全球經濟成長關鍵的力量。
 


二、徵求對象
 

有熱忱貢獻台灣產業創新發展之高階人才,對於海外企業之前瞻技術、商業模式、國際策略布局等有興趣,積極拓展自己的人脈、主動探索未知領域知識,並能與跨文化、跨領域之專業人才互動良好。
 


三、申請資格

 

  1. 國籍:申請人須有中華民國國籍

  2. 年齡:40歲(含)以下 (依報名截止日計)。

  3. 學經歷:不限,但須對欲申請之海外企業及其須具備之技術能力有相當程度的認識,具發展潛力及自我挑戰之企圖心,並於申請時詳細說明並提出相關證明。

  4. 英文能力:能與母語人士在研習環境及生活上流暢對談及表達之英文能力程度,並於申請時檢附民國(下同) 109年後取得之英文能力證明文件:

    • 多益 785分或以上

    • 托福紙本測驗(ITP) 543分 / 網路測驗(iBT) 72分或以上

    • 雅思 5.5分或以上

    • 全民英檢 中高級或以上

    • 英語系國家學士或同等級以上之學歷證明

    • (考量英文程度評估之有效期間,若非109年後取得者,請盡速進行測驗,並於報名截止期限前繳交成績證明

  5. 具有主動積極、獨立思考與作業能力,能與團隊充分溝通合作,且勇於與不同文化、技術背景的專業人才進行交流,對於將所學有服務熱忱,且可實際貢獻台灣產業者。

  6. 曾參與科技部產學研鏈結中心計畫(價創計畫)、研發成果萌芽計畫(萌芽計畫)、科研創業案源發掘及育成推動計畫(科創計畫)、創新創業激勵計畫(FITI計畫)等科技部科研創業相關計畫者尤佳。
     


四、申請方式

 

  1. 申請人須至計畫網站線上申請,報名系統網址:[待開放後公告]

  2. 請務必於報名截止日期前於報名系統送出,逾期不受理。

  3. 請依線上系統登錄格式內容,詳實完整填寫中英文資料並檢附相關證明文件。

  4. 申請人須覓兩位推薦人,並於報名系統如實填寫推薦人聯絡資訊,本計畫辦公室將請推薦人協助確認相關資訊。

  5. 網路報名資料一經送出不得修改,請務必確認申請內容是否已完整填寫並附上所有附件。
     


五、甄選程序與審查方式


 

  • 報名申請
    申請人於申請時,須選擇一個或多個欲前往之海外公司研習志願,於線上系統提交中英文構想書,並針對選擇的研習志願提出研習構想。
     
  • 三階段審查
    為使甄選流程公平公正,本計畫之各階段甄選,將由本計畫辦公室邀請相關領域專家及企業代表組成「評選委員會」進行甄選。
    1. 構想書審查
      公告構想書審查結果後,將通知通過審查者Global Mindset選訓活動細節與研習計畫書審查資訊。
       
    2. Global Mindset 選訓
      通過構想書審查的候選人方獲得參與本計畫辦理之Global Mindset 選訓資格,候選學員應全程參與選訓,於活動期間建立創新創業人脈、學習創業規劃與產業分析,並逐步完成研習計畫書。
       
    3. 研習計畫書審查
      以欲申請之研習志願為主軸,依指定之格式完成英文研習計畫書,並於計畫辦公室規定之期限內繳交。
       
  • 海外公司面試
    通過研習計畫書審查的候選人,得與通過研習計畫書之研習志願公司進行面試,並視需要進行電話或視訊訪談。本梯次面試時程依本計畫辦公室公告為主。
  • 核定公告
    本梯次實際核定學員人數將於海外公司面試結果與審查會議決定。獲選學員與本計畫辦公室簽訂合約後,將由本計畫辦公室協助簽證申請事宜,前往海外研習單位參加研習計畫。
上述程序如有異動,請依本計畫辦公室公告為主。
 

六、補助方式

 

  1. 補助金額:
    本計畫將補助學員研習期間之補助生活費,補助金額以新臺幣150萬元為原則,國外研習期間少於一年者,按比例發放。(請務必於行前衡量研習地區之消費水準與個人消費習慣)

     
  2. 前項補助生活費之核發分兩期撥付:
    • 第一期:第一至第六個月之補助生活費。雙方於簽訂合約且學員完成補助生活費請領手續後,於雙方約定之補助起始日前後30個日曆天內,將第一期補助生活費匯入學員指定之本人國內帳戶。
    • 第二期:第七至第十二個月之補助生活費。學員應依本計畫辦公室規定時程內繳交期中報告 (報告格式與內容依本計畫辦公室公告為主),經本計畫辦公室審核通過後,始撥付第二期補助生活費至學員指定之本人國內帳戶。
       

七、權利義務

 

  1. 本計畫為科技部為補助台灣人才赴外研習之計畫,故優先補助未曾受領政府公費補助出國之申請人,且曾受本計畫補助者不得再次申請。

  2. 公告入選之學員赴海外研習前,須參與行前培訓及團隊凝聚活動,並與本計畫辦公室簽署合約。若無法完成合約簽署或者主動放棄簽約者,視同放棄參與海外研習權利。

  3. 入選學員除應履行本計畫簡章之相關事項外,亦應確實遵守雙方簽署之合約與科技部相關規定。。

  4. 入選學員於簽署合約時,應覓具中華民國國民身分之連帶保證人一人,並配合辦理對保。連帶保證人須符合以下兩個條件之一,於簽約時提供相關證明文件:(1) 於我國現職服務機構服務兩年以上且最近之全年薪資所得在60萬元以上 (2) 具有250萬元以上並位於我國之不動產所有權。

  5. 前項連帶保證人若有下列情形之一,不得擔任學員之連帶保證人:(1)領取政府各類公費獲獎學金赴國外進修且尚未完成返國義務者 (2)雙或多重國籍者 (3)學員之配偶。

  6. 由於入選學員赴海外研習作業受簽證作業時程影響,確切赴海外時間依據入選學員之入境簽證文件為準,至遲須於本計畫辦公室公告之時程內抵達選定之海外研習機構。

  7. 入選學員赴海外研習若受簽證影響,無法取得本計畫規範之簽證赴外研習,恕不補助。如有特殊情況,請先知會計畫辦公室並徵得同意,計畫辦公室保留最終解釋和決定權。

  8. 學員於本計畫赴外研習期間,不得從事與研習目的無關之活動(包含原職)。若因故無法繼續參與本計畫之研習,除經本計畫辦公室書面同意外,須依合約負返還已受領之費用及相關賠償責任。

  9.  學員於本計畫赴外研習期間內應於指定期間內依規定繳交期中報告及期末報告,並通過審查(報告格式、內容,依本計畫辦公室公告為主)。如學員報告未通過報告審查,須依合約返還生活補助費並終止研習。

  10. 本計畫係科技部補助之研習計畫,科技部保留計畫執行方式與執行與否之最終決定權,包含但不限於本計畫辦公室配合科技部因天災、傳染病或其他不可抗力之事由或基於其他政策考量下片面終止本計畫。

  11. 獲本計畫補助之學員應負擔返國義務,返國義務包含返國服務、計畫宣傳義務與配合計畫辦公室後續追蹤,學員應於研習結束後五年內完成。其中返國服務之年限必須與所受領補助期限相同,計畫宣傳義務及後續追蹤內容依計畫辦公室公告為主。如完成研習之學員無法完成前述義務,本計畫保留請求全額生活補助費用、研習費用及損害賠償求償之權利。

  12. 科技部或本計畫辦公室不為結束研習之學員安排工作,學員須自行洽談覓職事宜。

  13. 其他學員權利義務以合約規範內容為準。
     


八、其他注意事項

 

  1. 本計畫之相關資訊與公告請密切注意本計畫網站
    聯絡窗口:財團法人國家實驗研究院科技政策研究與資訊中心產業創新人才海外培訓計畫辦公室
    聯絡電話:02-2737-7738、(02)2737-7747
    電子信箱:xtalent@narlabs.org.tw
    聯絡地址:10636臺北市和平東路二段106號1樓

     
  2. 本計畫簡章如有未盡事宜,本計畫辦公室及科技部隨時保留修訂公布及解釋之權利。
     
X Talent 2022 2nd Batch Host Companies List
查詢
AcuraStem Inc.

AcuraStem is a patient-based drug discovery platform company developing novel drug programs for neurodegenerative diseases. AcuraStem's iNeuroRx® technology platform combines patient-derived disease models with human genetic data. The company is led by experts in disease modeling, machine learning, and drug development.

Algen Biotechnologies, Inc.

Algen, a venture-backed preclinical stage biotech company, is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer and diseases with high unmet needs. Originated from UC Berkeley, Algen is the first to elegantly fuse high throughput, wide-scale gene editing and state-of-the-art machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen’s research group focuses on developing and applying novel functional genomics technologies to address scientific challenges in drug discovery and deliver innovative, patient-centric medicines for the toughest-to-treat diseases.

 

Apeximmune Therapeutics Inc.

Apeximmune Therapeutics seeks to harness the power of the immune system to treat and cure cancer. We discover and pioneer innovative therapeutic antibodies against novel targets to modulate immune cell activity and elicit durable efficacy in cancer. Apeximmune’s target discovery platform combines bioinformatics with biological assays to enable identification of novel immune modulating targets. Currently, antibodies for two immuno-oncology target programs in the pre-clinical stage are being actively developed with the goal of reaching IND status within 18 months.

BioLegend, Inc.

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value and with superior customer and technical support.

Chain Reaction Ltd.

「Chain Reaction Ltd.」前銳科技 簡介:
於2019年以70億美元把共同創辦的公司Mellanox賣給輝達(Nvidia)後不到一年,以色列創業家Alon Webman整合了一個全新的團隊重新成立了Chain Reaction。本公司為研發區塊鏈(Blockchain)系統硬體電路設計並整合加密技術(Cryptography)平台之新創公司。鎖定在未來區塊鏈爆發性成長趨勢中所謂「處處都需要加密(Cryptography everywhere)」的硬體需求。
本公司產品核心理念為提供高加速運算效能之硬體系統並結合優化區塊鏈零知識證明(Zero-Knowledge Proofs) 之加密演算法,以解決目前於雲端伺服器上區塊鏈計算之加速效能、隱私安全與規模化之三角難題。本公司產品為未來區塊鏈多元應用或元宇宙同態加密(Homomorphic Encryption)高運算需求應用舖路,主要研發產品為應用於雲端伺服器上之加密演算處理器(3PU, Privacy Preserving Process Unit);另外目前已開發完成第一代比特幣Crypto Mining ASIC產品,並於2022年開始量產製造銷售。
本公司研發總部設置於以色列,並分別在台灣新竹科學園區與美國矽谷設置分公司以招募半導體及加密技術研發人才,提供整合區塊鏈加密演算與IC設計並結合台灣半導體產業鏈的創新解決方案。
Chain Reaction Ltd. 曾獲Intel選入2020年以色列十大新創扶植公司,並為唯一硬體公司。

Genentech Inc.

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operate as a separate business unit within Roche. 

InfoValue Computing, Inc.

InfoValue pioneered high performance video streaming enabler products in 1997 to power mission critical solutions such as air force flight simulator, TV broadcast automation, telecom VOD. InfoValue then expanded to offer IPTV solutions to enterprise, healthcare, hospitality, senior living industries. 

Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City in 1849 in New York. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues. In 2020, 52% of the company's revenues came from the United States, 6% came from each of China and Japan, and 36% came from other countries.

Taboola

Taboola helps people find relevant content online, matching them with news stories, articles, blogs, videos, apps, products and other content they’re likely to want to explore.
How do we know what they’ll like? Using machine-learning algorithms, our technology analyzes hundreds of signals to capture exactly what kind of content is most likely to engage each individual. We do that more than 450 billion times a month for more than one billion unique users.

Since we opened our doors in 2006, we have grown to become the leading discovery platform on the open web, serving a combination of the world’s best brands and the most respected global publishers.

Taboola is headquartered in New York City with local offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, São Paulo, Beijing, Shanghai, Istanbul, Seoul, Sydney, Tokyo and Taiwan.

Taiwania Capital Management USA, Inc.

Taiwania Capital is a venture capital firm that was founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth.
We focus on investing in early-stage companies and have launched four funds till 2021.

We focus on financial returns but more than that, by linking technology and capital, we aspire to create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Tachyum s.r.o.

Tachyum is building the world’s fastest AI supercomputer to enable data centers that are more
powerful than the human brain. Its soon-to-be-launched Prodigy Universal Processor delivers
industry-leading performance, cost and power benefits to a $50B market that is expected to grow
at 20 percent a year. Early adopter customers and partners can use Prodigy software emulation
systems today that will enable them to transition their existing applications that demand high
performance and low power to run optimally on Prodigy processors, which ship in volume later this
year, with fully functional FPGA emulation system boards also available for pre-order.

- Tachyum is developing the next generation microprocessor and artificial intelligence chip – Prodigy™
- Prodigy is characterized by better performance (>3x) and lower energy consumption (up to 10x) compared to its competition
- Tachyum is in the final stage of development, preparing for mass production in 2022 and IPO in 2024

Proven Track Record
Founders and management have previously worked for nVidia, AMD and Intel; and successfully built  and exited Skyera which was acquired by WD and SandForce acquired for over US$377m.

Unique Universal Microprocessor/HPC/AI Architecture
will unlock unprecedented performance, power efficiency, and cost advantages, to solve the most complex problems in big data analytics, deep learning, mobile, and large-scale computing.

Vizuro LLC

Vizuro is an innovator and solution provider of Explainable AI in diverse sectors. We utilize our proprietary self-learning, causal inference technologies on a managed, data-science-as-a-service platform to quickly deploy bespoke applications in an expedited timeframe. We serve global clients in various sectors and sizes, ranging from Fortune 100 enterprises to startups

more